Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2022 07:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus,...
May 19, 2022 07:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the...
May 18, 2022 16:15 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will...
May 12, 2022 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK,...
April 20, 2022 07:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit

NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific...
March 23, 2022 07:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference

NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate...
March 21, 2022 07:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the fourth quarter and year ended...
March 17, 2022 07:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit

NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific...
March 07, 2022 07:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at 34th Annual ROTH Conference

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate...
January 05, 2022 07:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate...